Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Abstract Text:

Swati Biswas,Marta Guix,Cammie Rinehart,Teresa C Dugger,Anna Chytil,Harold L Moses,Michael L Freeman,Carlos L Arteaga,

We investigated whether TGF-beta induced by anticancer therapies accelerates tumor progression. Using the MMTV/PyVmT transgenic model of metastatic breast cancer, we show that administration of ionizing radiation or doxorubicin caused increased circulating levels of TGF-beta1 as well as increased circulating tumor cells and lung metastases. These effects were abrogated by administration of a neutralizing pan-TGF-beta antibody. Circulating polyomavirus middle T antigen-expressing tumor cells did not grow ex vivo in the presence of the TGF-beta antibody, suggesting autocrine TGF-beta is a survival signal in these cells. Radiation failed to enhance lung metastases in mice bearing tumors that lack the type II TGF-beta receptor, suggesting that the increase in metastases was due, at least in part, to a direct effect of TGF-beta on the cancer cells. These data implicate TGF-beta induced by anticancer therapy as a pro-metastatic signal in tumor cells and provide a rationale for the simultaneous use of these therapies in combination with TGF-beta inhibitors.

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Publishing Authors By Initials

S Biswas,M Guix,C Rinehart,TC Dugger,A Chytil,HL Moses,ML Freeman,CL Arteaga,

For similar virus diseases: tumor virus infections research abstracts see: virus diseases: tumor virus infections research

PUBMED ID PMID:

MEDLINE DATE:

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Journal of clinical investigation

VOLUME: 117

Page Numbers: 1305-13

Journal Abbreviation:

ISSN: 0021-9738

DAY: 5

MONTH: 04

YEAR: 2007

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7802877

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Keywords Mesh Terms:

KEYWORDS: Tumor Virus Infections

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Information

Substance Name: Transforming Growth Factor beta

Registry Number: 0

Grant and Affiliation Information for Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

AFFILIATION: Department of Cancer Biology, Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN 37232, USA.

Country: United States

AGENCY: United States NCI

GRANT: R01 CA 85492

ACRONYM: CA

MEDLINETA: J Clin Invest

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression Related Publications

• A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells.
• Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
• Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells.
• Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
• Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
• Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy.
• Knockdown of the Transforming Growth Factor-{beta} Type III Receptor Impairs Motility and Invasion of Metastatic Cancer Cells.
• Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.
• Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility.
• Neurophysiologic measurement of continuity in the sleep of fetuses during the last week of pregnancy and in newborns.
• Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
• Spinal muscular atrophy type I mimicking critical illness neuropathy in a paediatric intensive care neonate: Electrophysiological features.
• THE LABORATORY AS A PROPHYLACTIC MEASURE.
• Transforming Growth Factor {beta} Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab.
• Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
• [Clinical features of 17 patients with familial non medullary thyroid carcinoma.]
• [Distribution of Necator americanus and Ancylostoma duodenale in Santa Cruz, Bolivia]
• [Neonatal onset of organic acidemia (propionic) diagnosed by tandem mass spectrometry.]